<DOC>
	<DOCNO>NCT00416910</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , mitoxantrone , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Colony stimulate factor , G-CSF , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect combination chemotherapy . It yet know whether give combination chemotherapy alone effective combination chemotherapy together G-CSF treat patient chronic lymphocytic leukemia . PURPOSE : This randomized phase III trial study give combination chemotherapy together G-CSF see well work compare give combination chemotherapy alone treat patient relapsed stage I , stage II , stage III , stage IV chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without G-CSF Treating Patients With Relapsed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare rate remission , severe infection , side effect patient relapse advanced chronic lymphocytic leukemia treat fludarabine , mitoxantrone hydrochloride , cyclophosphamide v without filgrastim . Secondary - Compare overall survival , progression-free survival , quality remission patient . OUTLINE : This multicenter , randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fludarabine IV day 1-3 , mitoxantrone hydrochloride IV day 1 , cyclophosphamide IV day 1-3 . - Arm II : Patients receive fludarabine , mitoxantrone hydrochloride , cyclophosphamide arm I filgrastim ( G-CSF ) begin day 6 continue blood count recover . In arm , treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 165 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed relapse advanced chronic lymphocytic leukemia ( CLL ) Binet stage B C disease rapid disease progression , enlarge lymph node organ , severe Bsymptoms No prior nonresponse fludarabine combination therapy PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy &gt; 6 month No severe organ dysfunction No prior concurrent neoplasm , autoimmune hemolytic anemia , thrombocytopenia PRIOR CONCURRENT THERAPY : No three previous treatment regimen CLL ( fludarabine allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
</DOC>